ANgiogenic Function at NOrmal TErm on Placenta

Launched by CENTRE HOSPITALIER INTERCOMMUNAL CRETEIL · Jun 7, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how certain cells in the placenta, called trophoblasts, function during normal pregnancies that have reached full term (after 37 weeks). The main goal is to understand how these cells support the growth of blood vessels in the placenta, which is important for the health of both the mother and the baby. This research will involve both living participants and samples taken from the placentas after cesarean sections.

To be eligible for this study, participants should be women who are having a scheduled cesarean delivery at 37 weeks or more of pregnancy. This includes those with normal pregnancies as well as those with certain complications like gestational diabetes or pregnancy cholestasis. However, women who are under 18, have multiple pregnancies, or have specific health issues like pre-eclampsia or major fetal malformations cannot join. If you participate, you can expect to provide placenta samples after your delivery, which will help researchers learn more about how the placenta functions in different pregnancy situations.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Pregnancies with scheduled cesarean delivery \>37 weeks of amenorrhea:
• • strictly normal pregnancies
• • complicated pregnancies of gestational diabetes, insulin-treated or not
• • complicated pregnancies due to pregnancy cholestasis
• • spontaneous or in vitro fecondation (IVF) / Intracytoplasmic sperm injection (ICSI) pregnancies with or without oocyte donation
• Exclusion Criteria:
• • Patient's opposition
• • Age \< 18 years old
• • Women under the protection of justice
• • Multiple pregnancy
• • Known major fetal malformation
• • Pre-eclampsia and intrauterine growth retardation
• • Placental insertionnomaly
• • Type 1 diabetes
• • HIV-positive patient with HIV/hepatisis C virus (HCV) regardless of viral load
• • Patient in labour at the time of Caesarean section
• • Patient whose medical history results in medication being taken in pregnancy courses that may interfere with the biology of the trophoblast (immunomodulators in case of autoimmune diseases, anti-rejection drugs in case of transplant patients)